Phase I/II study of letrozole and sorafenib as first-line therapy of hormone-receptor positive (HR plus ) metastatic breast cancer (MBC).

被引：0
|
作者：
Tan, Antoinette R.
Wong, Serena Tsan-Lai
Warren, Robert D.
Eng-Wong, Jennifer
Liu, Minetta C.
Zelnak, Amelia Bruce
Lin, Yong
Shih, Weichung
Ganesan, Shridar
Grana, Generosa
Isaacs, Claudine
Toppmeyer, Deborah
机构：
[1] Rutgers Canc Inst New Jersey, New Brunswick, NJ USA
[2] Lombardi Canc Ctr, Washington, DC USA
[3] Genentech Inc, San Francisco, CA 94080 USA
[4] Mayo Clin, Rochester, MN USA
[5] Emory Univ, Winship Canc Inst, Atlanta, GA 30322 USA
[6] Cooper Univ Hosp, Camden, NJ USA
[7] Lombardi Comprehens Canc Ctr, Washington, DC USA
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2014年 / 32卷 / 15期
关键词：
D O I：
10.1200/jco.2014.32.15_suppl.531
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
531
引用
收藏
页数：1
相关论文
共 50 条
  • [21] Genomic testing and uptake of alteration-targeted therapies among patients with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC)
    Mahadevia, Himil
    Chandra, Simran
    Gosch, Kensey
    Khamees, Ibrahim
    Sharma, Parth
    Gast, Kelly C.
    Pluard, Timothy J.
    Hensing, Whitney L.
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [22] Phase 1b study of orteronel in postmenopausal women with hormone-receptor positive (HR plus ) metastatic breast cancer.
    Rampurwala, Murtuza M.
    Burkard, Mark E.
    Wisinski, Karl Braun
    Chimeh, Sima Ehsani
    Zeal, Jamie
    Koehn, Tamara
    Champeny, Tone L.
    Rettig, Joan
    Kim, KyungMann
    Kolesar, Jill
    Tevaarwerk, Amye
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [23] Randomized phase II study of eribulin mesylate (E) with or without pembrolizumab (P) for hormone receptor-positive (HR plus ) metastatic breast cancer (MBC).
    Tolaney, Sara M.
    Barroso-Sousa, Romualdo
    Keenan, Tanya
    Trippa, Lorenzo
    Hu, Jiani
    Luis, Ines Maria Vaz Duarte
    Wulf, Gerburg M.
    Spring, Laura
    Sinclair, Natalie Faye
    Andrews, Chelsea
    Pittenger, Jessica Demeo
    Richardson, Edward T.
    Dillon, Deborah
    Lin, Nancy U.
    Overmoyer, Beth
    Partridge, Ann H.
    VanAllen, Eliezer
    Mittendorf, Elizabeth A.
    Winer, Eric P.
    Krop, Ian E.
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
  • [24] Relevance of serum HER2 extracellular domain (sECD) in EGF30008, a study of letrozole ± lapatinib in patients (pts) with hormone-receptor positive (HR plus ) metastatic breast cancer (MBC)
    Platek, G. T.
    Koehler, M.
    Gagnon, R.
    O'Rourke, L.
    Maltzman, J. D.
    Press, M.
    Johnston, S.
    Pegram, M.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [25] Phase III trial evaluating the addition of bevacizumab to letrozole as first-line endocrine therapy for treatment of hormone-receptor positive advanced breast cancer: CALGB 40503 (Alliance).
    Dickler, Maura N.
    Barry, William Thomas
    Cirrincione, Constance T.
    Ellis, Matthew James
    Moynahan, Mary Ellen
    Innocenti, Federico
    Hurria, Arti
    Rugo, Hope S.
    Lake, Diana
    Hahn, Olwen Mary
    Schneider, Bryan P.
    Tripathy, Debu
    Winer, Eric P.
    Hudis, Clifford A.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)
  • [26] Phase II trial of combination therapy with metronomic capecitabine (C) and fulvestrant (F) in the treatment of hormone receptor-positive metastatic breast cancer (HR plus MBC)
    Blakely, L. J.
    Schwartzberg, L. S.
    Wang, G.
    Somer, B. G.
    Wheeler, B. M.
    Stepanski, E. J.
    Walker, M.
    Johns, A.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [27] Phase I/II Trial of Sorafenib in Combination with Vinorelbine as First-Line Chemotherapy for Metastatic Breast Cancer
    Ferrario, Cristiano
    Strepponi, Ivan
    Esfahani, Khashayar
    Charamis, Helen
    Langleben, Adrian
    Scarpi, Emanuela
    Nanni, Oriana
    Miller, Wilson H., Jr.
    Panasci, Lawrence C.
    PLOS ONE, 2016, 11 (12):
  • [28] A phase I study of docetaxel plus cyclophosphamide in solid tumors followed by a phase II study as first-line therapy in metastatic breast cancer
    Trent, JC
    Valero, V
    Booser, DJ
    Esparza-Guerra, LT
    Ibrahim, N
    Rahman, Z
    Vernillet, L
    Patel, S
    David, CL
    Murray, JL
    Cristofanilli, M
    Hortobagyi, GN
    CLINICAL CANCER RESEARCH, 2003, 9 (07) : 2426 - 2434
  • [29] Efficacy of Letrozole as First-Line Treatment of Postmenopausal Women with Hormone Receptor-Positive Metastatic Breast Cancer in Korea
    Beom, Seung Hoon
    Oh, Jisu
    Kim, Tae-Yong
    Lee, Kyung-Hun
    Yang, Yaewon
    Suh, Koung Jin
    Moon, Hyeong-Gon
    Han, Sae-Won
    Oh, Do-Youn
    Han, Wonshik
    Kim, Tae-You
    Noh, Dong-Young
    Im, Seock-Ah
    CANCER RESEARCH AND TREATMENT, 2017, 49 (02): : 454 - 463
  • [30] Lapatinib plus Letrozole as First-Line Therapy for HER-2+ Hormone Receptor-Positive Metastatic Breast Cancer (vol 15, pg 122, 2010)
    Schwartzberg, Lee S.
    Franco, Sandra X.
    Florance, Allison
    O'Rourke, Lisa
    Maltzman, Julie
    Johnston, Stephen
    ONCOLOGIST, 2010, 15 (03): : 327 - 327
12345